Display Settings:

Format

Send to:

Choose Destination
    Cancer Cell Int. 2011 Aug 16;11:28.

    Murine mammary tumor cells with a claudin-low genotype.

    Source

    Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, ON N1G2W1, Canada. rmoorehe@uoguelph.ca.

    Abstract

    ABSTRACT:

    BACKGROUND:

    Molecular classification of human breast cancers has identified at least 5 distinct tumor subtypes; luminal A, luminal B, Her2-enriched, basal-like and claudin-low. The claudin-low subtype was identified in 2007 and is characterized by low expression of luminal differentiation markers and claudins 3, 4 and 7 and high levels of mesenchymal markers. Claudin-low tumors have a reported prevalence of 7-14% and these tumors have a poor prognosis.

    RESULTS:

    In this study we report the characterization of several cell lines established from mammary tumors that develop in MTB-IGFIR transgenic mice. Two lines, RM11A and RJ348 present with histological features and gene expression patterns that resemble claudin-low breast tumors. Specifically, RM11A and RJ348 cells express high levels of the mesenchymal genes Zeb1, Zeb2, Twist1 and Twist2 and very low levels of E-cadherin and claudins 3, 4 and 7. The RM11A and RJ348 cells are also highly tumorigenic when re-introduced into the mammary fat pad of mice.

    CONCLUSIONS:

    Mammary tumor cells established from MTB-IGFIR transgenic mice can be used as in vitro and in vivo model systems to further our understanding of the poorly characterized, claudin-low, breast cancer subtype.

    PMID:
    21846397
    [PubMed]
    PMCID:
    PMC3170246
    Free PMC Article

    Images from this publication.See all images (2) Free text

    Figure 2
    Figure 1

      Supplemental Content

      Icon for BioMed Central Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk